Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.
- Authors
- Dejan, J[Dejan, Juric]; Rugo, HS[Rugo, Hope S.]; Chia, SKL[Chia, Stephen K. L.]; Lerebours, F[Lerebours, Florence]; Ruiz-Borrego, M[Ruiz-Borrego, Manuel]; Drullinsky, P[Drullinsky, Pamela]; Ciruelos, EM[Ciruelos, Eva M.]; Neven, P[Neven, Patrick]; Park, YH[Park, Yeon Hee]; Arce, CH[Arce, Christina H.]; Gu, E[Gu, Ennan]; Joshi, M[Joshi, Mukta]; Roux, E[Roux, Estelle]; Akdere, M[Akdere, Murat]; Turner, NC[Turner, Nicholas C.]
- Issue Date
- 1-Jun-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.